Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS) featuring both neuroinflammatory and neurodegenerative aspects. Available therapies modulate immune cell behavior, thereby effectively preventing relapses and reducing disability. 1 However, to date no treatment for neurodegeneration during progressive stages is available. Histopathologically, relapses are driven by focal inflammatory demyelination, leading to oligodendroglial loss and axonal injury. 2 Remyelination, which is mediated by the recruitment and differentiation of resident oligodendroglial precursor cells (OPCs), restores axonal conduction and contributes to clinical recovery. 3 Because there is an increasing loss of neuronal function during the progressive stages of MS, stimulation of endogenous remyelination could have a prodigious therapeutic impact. The number of potential drug candidates in the translational pipeline has expanded significantly over the past 5 years. We therefore expand our previous review 4 by discussing the newest developments in the field of remyelination in MS.
also restricted by several extrinsic and intrinsic OPC differentiation inhibitors. 12 Mouse models of remyelination Due to limitations of studies involving human tissue, researchers have focused on animal models to investigate remyelination. However, given the complexity of MS and the heterogeneity among MS patients, there is no comprehensive animal model of this disease. The most common mouse model to mimic the immunological characteristics of MS is myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE), which over the years has been refined to incorporate features of demyelination and axonal damage. 13 The major limitation of EAE is that lesions are primarily detected in the spinal cord although this can be circumvented by stereotaxic injection of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α and interferon (IFN)-γ directly into the brain of MOG-immunized mice. 14 In addition, chronic relapsing-remitting-type EAE can be generated using NOD/Lt or SJL mice. 15, 16 A model system more suitable for studying remyelination is the cuprizone (N,N′-bis(cyclohexylideneamino)oxamide) model. Cuprizone is a copper chelator that impairs cytochrome oxidase activity in mitochondria, primarily of oligodendrocytes leading to apoptosis. This model, initially characterized by Blakemore, 17 has been used extensively to study demyelination and naturally occurring remyelination via oligodendrogenesis following the removal of the toxin from the diet. As the blood-brain barrier (BBB) remains intact during cuprizone challenge, 18 the contribution of the adaptive immune system is negligible, whereas microgliosis and astrogliosis are readily observed. 19 This model therefore provides the unique opportunity to investigate demyelination and remyelination with minimal interference from peripheral immune cells. In a recent study, the cuprizone model was combined with EAE, providing the opportunity to study the impact of adaptive immunity in demyelinating lesions. 20 Compared to EAE, the cuprizone model however, yields highly reproducible results with consistent levels of demyelination and remyelination.
Another systemic MS animal model is Theiler's murine encephalomyelitis virus (TMEV), which is a single-stranded RNA virus. Upon infection, susceptible mouse strains develop severe multifocal CNS inflammation, including activation/infiltration of microglia, macrophages, T cells, and B cells, 21 with a chronic phase characterized by inflammatory demyelination and axonal degeneration, bearing some similarity to progressive MS. 22 Finally, the toxin, lysolecithin can be injected into different regions of the CNS including the spinal cord 23 and the corpus callosum, 24 inducing rapid demyelination leading to OPC recruitment as well as differentiation and remyelination. A similar time course of demyelination and remyelination can also be achieved with injections of ethidium bromide. In contrast to lysolecithin, which specifically degenerates myelin membranes, this toxin causes a depletion of glial cells. 25 
Current remyelination therapies
Current MS therapies are primarily immunomodulatory and efficiently reduce relapse rates and magnetic resonance imaging (MRI) measures of inflammation. Aside from the identification of candidate drugs inducing myelin repair in basic research and clinical trials investigating regenerative compounds, research has also been focused on detecting additional regenerative properties of existing drugs used for other indications.
Remyelination therapies in clinical trials

Clemastine
The first-generation histamine H1 receptor blocker clemastine was identified as a potentially remyelinating drug in a high-throughput in vitro screening. 26 Its remyelinating effect was confirmed, 26 resulting in a clinical study in 50 RRMS patients (ReBUILD, 27 NCT02040298). The effect of orally administered clemastine on chronic demyelinating optic neuropathy was investigated using the shortening of the P100 latency delay in visual evoked potentials (VEPs). The drug was found to reduce P100 latency by 3.2 ms/eye if the trial results were analyzed as a "delayed treatment trial," or 1.7 ms/eye when considered as a "crossover trial." 27 
GSK239512
This orally administered, CNS-penetrant antihistamine drug, which targets the H 3 receptor, was originally developed to treat schizophrenia and Alzheimer's disease 28, 29 but was found to be ineffective for these indications.. The efficacy of GSK239512 for remyelination was tested in a small phase II, randomized, parallel-group, placebo-controlled, double-blind, international, multicenter study of adults with RRMS (NCT01772199). While the drug was well tolerated, unfortunately the trial failed to meet its primary and secondary endpoints. However, in a post hoc analysis using magnetization transfer ratio (MTR) to assess in vivo myelin content, GSK239512 treatment resulted in small mean improvements in lesional MTR relative to placebo. 30 
Opicinumab
Opicinumab is an antibody directed against leucinerich repeat and immunoglobulin-like domain-containing Nogo receptor-interacting protein 1 (LINGO-1), a transmembrane protein exclusively expressed in the non-neuronal cells of the CNS. Specific loss of LINGO-1 in vitro as well as in vivo enhances myelin sheath formation and myelination, 31, 32 and the application of specific anti-LINGO-1 antibodies was found to reduce EAE severity. Two trials have investigated the efficacy of opicinumab in optic neuritis (ON 33 ) and RRMS (NCT01864148), respectively. The RENEW trial in ON showed an improvement in the recovery of optic nerve conduction latency as measured by VEP, while the SYNERGY trial did not meet its primary endpoint. However, based on post hoc analyses revealing an increased clinical effect in a subgroup of patients (MS for no more than 20 years and baseline MRI suggestive of relative myelin loss and greater structural integrity), the ongoing AFFINITY trial was launched, which is geared more toward the better-responding population (NCT03222973).
GNbAC1
GNbAC1, which is a humanized antibody directed against the envelope protein (ENV) of multiple sclerosis-associated retrovirus (MSRV), is yet another candidate likely affecting remyelination and neurorepair. Generally silenced through epigenetic control, certain environmental factors such as viruses (e.g. Epstein-Barr virus (EBV) and HHV8) lead to its reexpression in susceptible cells. 34 ENV protein is present in close proximity to OPCs in normal-appearing white matter (NAWM) in the brains of MS patients and is capable of directly interfering with OPC differentiation via activation of Toll-like receptor 4. 35 The clinical trial (CHANGE-MS, NCT02782858) enrolling 270 patients showed a significant benefit of GNbAC1 on cortical and thalamic atrophy, with relative volume loss reductions of 31% and 72%, respectively. Moreover, the number of T1 hypointense lesions (i.e. black holes) was reduced by 63% versus the control group. Furthermore, there was a benefit in MTR in both NAWM and cerebral cortical bands, suggesting an effect on remyelination.
Ocrelizumab
Ocrelizumab is a monoclonal antibody directed against the B cell surface marker CD20 and is used for both primary progressive multiple sclerosis (PPMS) and RRMS. 36, 37 While in RRMS ocrelizumab was found to be more effective than IFN-β-1a, the results of the placebo-controlled PPMS trial should be viewed with caution. The primary endpoint of this study, that is, disability progression confirmed at 3 months, was reached with only p = 0.03 and the relative risk reduction was 24%. The study, based on the previous experience with rituximab, which is another monoclonal anti-CD20 antibody, had relatively restrictive entry requirements, including age between 18 and 55 years and the presence of oligoclonal bands in cerebrospinal fluid (CSF). This resulted in a relatively young study population with a comparatively short disease duration and high residual inflammatory activity, which is underlined by the fact that 24.7%-26.5% of the patients still had gadolinium-enhancing lesions on their baseline MR scans. As a result, it is conceivable that ocrelizumab's effect on disability progression in PPMS is primarily mediated by its anti-inflammatory properties (as convincingly shown in the RRMS trial), rather than being based on specific anti-degenerative or neuroprotective mechanisms. On the other hand, post hoc analyses also showed a moderate treatment effect in older patients with longer disease duration and less inflammatory activity, so a final conclusion on ocrelizumab's antidegenerative properties is currently difficult to draw.
Simvastatin
Statins, which are widely used to treat hypercholesterolemia, were shown to stimulate OPC differentiation. Based on these and other studies, the SIMCOMBIN trial investigated whether simvastatin could be efficacious as an add-on therapy to IFN-β in RRMS. 38 Using annual relapse rate as the primary endpoint, the study was negative. However, a second trial (MS-STAT) enrolling 140 secondary progressive multiple sclerosis (SPMS) patients showed that simvastatin led to a significant 43% reduction in the mean annualized brain atrophy rate. 39 A larger MS-STAT2 study is now planned to recruit 1180 SPMS patients to investigate whether simvastatin can slow progression in SPMS over a 3-year period (NCT03387670).
Biotin
Biotin is a B vitamin family coenzyme thought to increase myelin production by increasing adenosine triphosphate (ATP) production as well as stimulating fatty acid synthesis. 40 In a first trial published in 2016 (MS-SPI 41 ) progressive MS patients received biotin daily and were monitored for disability reversal as defined by an Expanded Disability Status Scale (EDSS) score decrease of ⩾1 point (⩾0.5 points for EDSS 6-7) or a ⩾20% decrease in a timed 25-foot walk (TW25). This primary endpoint was reached by 12.6% of the biotin-treated patients. A second trial investigating high-dose biotin (MS-ON) included 93 patients with unilateral or bilateral optic neuropathy (ON) with persistent visual loss and worsening of visual acuity. Here, in a subgroup of 31 patients with progressive ON, biotin treatment improved visual acuity. Building on the results of the SPI study, further progressive MS trials were launched aiming at confirming previous results with more patients and refined readouts (NCT03302806, NCT02936037).
Quetiapine fumarate
Quetiapine, which is an atypical antipsychotic drug administered in the form of a fumarate salt, has been reported to stimulate the differentiation of neural progenitors into oligodendrocytes and to increase the synthesis of myelin basic protein (MBP). It is thought to increase oligodendroglial maturation and to prevent toxic demyelination in C57BL/6 mice by cuprizone. 42 These rodent studies have prompted a phase I study currently underway to determine this compound's safety and tolerability in MS patients (NCT02087631). Notably, quetiapine fumarate is chemically similar to dimethyl fumarate, which was approved for the treatment of RRMS in 2013. However, while it has been established that dimethyl fumarate exerts neuroprotective effects in neuroinflammation via the NF-E2-related factor 2 (Nrf2) antioxidant pathway, 43 effects on remyelination have not been studied thus far.
Domperidone
In the clinical setting, domperidone, a D2/D3 dopamine receptor antagonist, is widely used to treat nausea and vomiting. However, more than 30 years ago, it was already shown to increase the production of prolactin in humans. 44 Prolactin stimulates remyelination in animal models, 45 which prompted the initiation of two phase II clinical trials. The aim of the first is to elucidate whether domperidone can reduce disability progression in SPMS (NCT02308137), while the second investigates its effects in RRMS (NCT02493049).
Antisemaphorin 4D (VX15/2503)
Semaphorins, the name of which is derived from the well-known naval flag-based communication system, have pleiotropic effects in a multitude of different contexts ranging from development to regulating the immune system. 46 However, they also exert direct effects on OPC migration and play an important role in T cell activation. 47 One member of the semaphorin family, semaphorin 4D (Sema4D), is upregulated in OPCs upon spinal cord injury 48 and was found to induce the collapse of process extensions in OPCs. 49 Blocking Sema4D resulted in a strong reduction of inflammatory activity in EAE, 50 which prompted the initiation of a phase I clinical trial investigating the safety and tolerability of humanized anti-Sema4D monoclonal antibody VX15/2503 in MS patients (NCT01764737).
Remyelinating therapies with preclinical data
IRX4204
This specific agonist of retinoic acid receptor gamma (RXR-γ) was found to boost OPC differentiation in vitro 51 and in vivo. 51 In addition to its positive effect on gliogenesis, IRX4204 was also reported to inhibit CNS inflammation in EAE. This is likely achieved by shifting T cell balance, inhibiting potentially detrimental helper T cells and promoting regulatory T cell differentiation. 52, 53 Thus, IRX4204 may be of therapeutic value for treating MS by simultaneously targeting immune and neural cells. This dual role in this context is currently being investigated by a group of scientists in collaboration with Io Therapeutics, Inc. (Santa Ana, CA).
Kappa opioid
The kappa opioid receptor (KOR) is a part of the endogenous opioid system and was identified as promoting oligodendrocyte differentiation and myelination in purified oligodendroglial co-cultures. 54 The lead compound U-50488 was effective in promoting differentiation, accelerated remyelination in vivo, and enhanced the differentiation of pluripotent stem cellderived OPCs into mature oligodendrocytes. 54 
Spingosine-1-phosphate receptor modulators
In our previous review, we discussed the effects of fingolimod, a sphingosine-1-phosphate (S1P) receptor modulator preventing the egress of lymphocytes from lymph nodes. 55 However, fingolimod is also known to cross the BBB into the brain, where it modulates the behavior of resident cell populations such as immature oligodendrocytes via RhoA signaling 56 and can enhance remyelination. 57 Siponimod, another S1P receptor modulator particularly targeting the receptor subtypes S1P1 and S1P5, was found to rescue GABAergic transmission in the striatum of EAE mice and to prevent the loss of GABAergic interneurons. Moreover, it reduced astrogliosis and microgliosis. 58 Investigating its effects in SPMS, a clinical study found that siponimod reduced confirmed disability progression (CDP) by 21%, as well as annualized relapse rate (ARR) by 55%, over 3 months of treatment (EXPAND study 59 ). This may reflect the fact that even though patients had to be free of relapses for 6 months before inclusion, approximately 25% still had gadolinium-enhancing (Gd+) T1 lesions at baseline, which is indicative of inflammatory activity. Moreover, no PPMS patients were enrolled, which leads to the question as to whether neurodegeneration without any residual inflammation can be effectively targeted.
The γ-secretase inhibitor quercetin Multiple molecular signaling cascades operate in parallel to inhibit OPC differentiation and remyelination of MS lesions. 12 For example, inhibiting oligodendroglial Notch signaling through γ-secretase has already been shown to significantly enhance clinical recovery and remyelination in EAE. 60 Besides the Notch pathway, Wnt signaling has also been shown to affect (re-)myelination by nuclear translocation of β-catenin, a process termed canonical Wnt signaling. In the nucleus, β-catenin binds to transcription factor 4 (Tcf4) which, in turn, delays myelin repair. 61, 62 However, there is the important caveat that indiscriminate inhibition of Wnt is likely to interfere with both canonical and noncanonical Wnt signaling, which regulates a multitude of different cell functions. 63, 64 Arguably, the most promising agent currently available for selective inhibition of canonical Wnt signaling is the flavonoid quercetin, which has already been investigated in colonic carcinoma and which was found to strongly suppress the binding of Tcf complexes to specific DNA-binding sites and to disrupt binding of β-catenin to Tcf-4. 65 Quercetin could therefore provide a pharmacological approach for highly selective therapeutic inhibition of Wnt signaling.
Teriflunomide
Teriflunomide, an oral first-line RRMS treatment in the United States and the European Union (EU), is the active metabolite of the antirheumatic drug leflunomide. Its immunomodulatory effects are thought to be mainly based on an inhibition of de novo pyrimidine synthesis, exerting a cytostatic effect on proliferating lymphocytes. 66 Short-term teriflunomide stimulation was found to significantly promote oligodendroglial differentiation, involving direct effects on major myelin transcription factors as well as on nuclear protein shuttling components. 67 Moreover, pulsed teriflunomide treatment also resulted in the generation of mature oligodendrocytes that efficiently myelinate axons in vitro. It remains to be seen whether it can also drive remyelination in vivo. If so, this could provide a functional explanation for the observed reduction of disability progression in clinical trials (TEMSO, NCT00134563, and TOWER, NCT00751881). 68, 69 Remyelination: from promise to reality Even though significant progress has been made since the first introduction of IFNs in the early 1990s, there is still no effective treatment for the degenerative aspects of MS. Halting continuous worsening and improvement of acquired deficits remain urgent unmet clinical needs. Luckily, the research pipeline directed toward remyelination and repair contains several agents that have shown promise in both initial trials as well as animal models. One of the priorities of MS research is the need to develop techniques that can effectively measure the efficiency of repair/remyelination in a clinical trial setting. In addition, in developing such therapies, we should always bear in mind that drug safety plays an ever-increasing role, as sadly shown by the example of daclizumab. It is therefore our primary responsibility to carefully assess promising drugs by relying as much as possible on translational approaches.
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